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Maleimides remain the reagents of choice for the preparation of therapeutic and imaging
protein conjugates despite the known instability of the resulting products that undergo
thiol-exchange reactions in vivo. Here we present the rational design of carbonylacrylic
reagents for chemoselective cysteine bioconjugation. These reagents undergo rapid thiol
Michael-addition under biocompatible conditions in stoichiometric amounts. When using
carbonylacrylic reagents equipped with PEG or fluorophore moieties, this method enables
access to protein and antibody conjugates precisely modified at pre-determined sites.
Importantly, the conjugates formed are resistant to degradation in plasma and are biologically
functional, as demonstrated by the selective imaging and detection of apoptotic and HER2þ
cells, respectively. The straightforward preparation, stoichiometric use and exquisite cysteine
selectivity of the carbonylacrylic reagents combined with the stability of the products and the
availability of biologically relevant cysteine-tagged proteins make this method suitable for the
routine preparation of chemically defined conjugates for in vivo applications.
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Protein bioconjugation has a crucial role in the developmentof novel biologically active protein conjugates forapplications in biology and medicine1–3. The
chemoselectivity and mildness of the process are key to
precisely install modifications at pre-determined sites without
disturbing the structure, function and activity of the protein4–6.
Reactivity, accessibility and abundance of a particular amino acid
side chain are key aspects required to achieve selective
modification of one certain residue over all other proteinogenic
amino acids. Among these, cysteine (Cys) remains the amino acid
of choice due to its low abundance and the high nucleophilicity of
the sulfhydryl side chain7. Indeed, most protein conjugates used
in the clinic, for example antibody-drug conjugates (ADCs)2,8, are
prepared using Cys bioconjugation methods.
Several alkylation reagents and Michael acceptors have been
and continue to be reported for Cys bioconjugation7,9. More
recently, selective arylation of Cys has also been demonstrated as
a viable strategy for Cys selective bioconjugation. Cys arylation
has been achieved by reacting perfluoroaryl reagents with a
sequence specific (Phe-Cys-Pro-Phe, termed ‘p-clamp’)10 that
was genetically encoded into a protein or by using organometallic
palladium reagents11.
Despite the developments in the field of Cys bioconjugation,
maleimides are still the most commonly used reagents, mainly
due to fast aqueous reaction kinetics, easy synthesis of modified
maleimide reagents and the fact that does not require extensive
genetic engineering of the protein target. For instance, the
Food and Drug Administration approved ADC—Brentuximab
vedotin12—is prepared by conjugation of a maleimide linker-drug
molecule to Cys residues on an antibody. However, it is now
well-documented that the thio-succinimidyl conjugates formed
undergo rapid exchange reactions with thiols present in plasma
leading to the release of the maleimide13–15. In the case of ADCs,
this can lead to toxicity, as the product of the thiol-exchange
reaction is a highly potent cytotoxic drug. Thus, there is a
pressing need for the development of methods to ready build
protein and antibody conjugates in a manner that allows for
site-selective and irreversible installation of probes and drugs at
specific sites within their sequence.
In the specific case of maleimides, strategies have been pursued
to enhance the natively slow hydrolysis kinetics in order to
generate a stable ring-opened maleimide. This has been achieved
either by genetic engineering of the sequence adjacent to Cys13 or
by chemical introduction of a basic amino group on the
maleimide structure16–18. These approaches lead to conjugates
that are more stable in vivo, but require extensive sequence
engineering, use reagents that result in a less efficient conjugation
and often result in heterogenous mixtures of hydrolysed versus
non-hydrolysed conjugates. Replacement of the endocyclic olefin
by an exocyclic one has also been shown to reduce thiol-exchange
reactions19. However, the slower kinetics of the reaction of
exocyclic maleimides with Cys requires a larger excess of reagents
to achieve useful conversions in proteins. Furthermore, an open
form of a maleimide has been shown to be a useful scaffold when
conjugated to a coumarin for fast thiol-quantification glutathione
reductase20.
In an attempt to provide an optimal Cys-bioconjugation
method, we explored simple carbonylacrylic derivatives to
identify those that were highly reactive for Cys in aqueous
conditions at near neutral pH and afforded products resistant to
degradation that might be used for in vivo therapeutic and
imaging applications.
Results
Design of carbonylacrylic reagents for Cys modification. We
began our study by reacting the protected amino acid Boc-Cys
methyl ester 1 with the commercially available carbonylacrylic
reagent, 3-benzoylacrylate 2a. Remarkably, the reaction was
complete (99% yield) using stoichiometric amounts of 2a in less
than 2min at room temperature and could be conducted in 30%
MeCN in sodium phosphate buffer (NaPi, pH 8.0, 50mM) in
open air (Fig. 1a). Importantly, in a competition experiment
performed under the same reaction conditions, Boc-Lysine(Lys)
methyl ester 4 remains unreactive and only the Cys adduct is
formed, demonstrating well the high chemoselectivity of 2a
towards Cys (Fig. 1b). Considering the structural simplicity of 2a,
we designed a series of variants with the aid of quantum
mechanical calculations, balancing reactivity and functionality at
both ends of the reacting alkene. Ketones, esters and amides 2b–d
were considered aiming to find a highly reactive and extensible
reagent that could be used for rapid Cys selective and irreversible
protein conjugation. An abbreviated Cys (MeS" ) was used in the
calculations as a model sulfhydryl nucleophile. A quickly
evaluable reactivity predictor such as the energy gap (DE)
between the highest occupied molecular orbital of MeS" and the
lowest unoccupied molecular orbital of the Michael acceptor, was
first used to screen the reactivity of different carbonylacrylic
candidates (a smaller highest occupied molecular orbital–lowest
unoccupied molecular orbital gap would indicate a higher
reaction rate)21. Such analysis predicted that trans-1,
2-disubstituted olefins bearing either a methyl ketone and an
ester (2b, DE¼ 4.5 eV) or a phenyl ketone and an amide
(2c, DE¼ 4.4 eV) should have a reactivity comparable to that
of 2a (DE¼ 4.2 eV) and maleimide (DE¼ 4.3 eV). Further
refinement of this descriptor through more elaborate transition
state calculations (Supplementary Figs 1 and 2 and
Supplementary Table 1 and Supplementary Data 1), confirmed
that 2a, 2b and 2c are within the same reactivity window than the
reference maleimide (see relative calculated reaction rates,
Fig. 1c). Of note, while an amide is tolerated at one side of the
double bond, offering great synthetic advantages for
bioconjugation, the presence of amides at both ends of the
olefin such as in 2d, (DE¼ 5.1 eV), reduces its calculated
reactivity up to seven orders of magnitude due to its inability
to stabilize the negative charge accumulated in the
carbonylacrylamide upon thiolate addition. Our experimental
results were in accordance with these predictions as
carbonylacrylic derivatives 2a–c gave a complete product
formation (Fig. 1a,d) and the reaction proceeded with fast
kinetics (k2 (2a)¼ 40.2M" 1s" 1 and k2 (2c)¼ 10.9M" 1s" 1;
Fig. 1e and Supplementary Fig. 3). Finally, a competition
experiment followed by 1H-NMR against the commonly used
N-methyl maleimide, showed a similar product distribution
indicating a comparable reaction rate for 2a, 2b and the
maleimide derivative (Supplementary Fig. 4).
Next, we studied and compared the stability of thioether
conjugates obtained using the novel carbonylacrylates with those
obtained using conventional maleimides. Using a kinetic assay
with chromogenic thiol adducts, we demonstrated that 5, which
was prepared from a carbonylacrylic derivative, is fully stable
when compared with the thio-succinimidyl derivative 6 at pH 7.4
(Fig. 1f). In addition, reaction of 3c with the natural thiol
nucleophile glutathione (GSH), showed no C–S cleavage for over
a week as assessed by NMR and mass spectrometry
(Supplementary Figs 5 and 6).
Reaction optimization for protein modification. With a
new class of irreversible Michael-acceptor reagents that are
Cys-selective in hand, we further explored their use for protein
bioconjugation. The carbonylacrylic derivatives 2a–d were
evaluated for the labelling of Annexin V, a protein used as an
apoptosis imaging agent that contains a free, hindered Cys at
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position 316 (Table 1 and Supplementary Figs 8–12)22. Using 25
equivalents of 2a–d in TrisHCl (pH 8.0, 50mM) for 27 h at 25 !C,
we found that only 2c gave a useful conversion to the
corresponding thioether adduct. Both 2a and 2b, featuring ester
motifs, suffer from partial hydrolysis under the conditions tested.
Based on these results, we decided to optimize the reaction
conditions using 2c and found that for Annexin V complete
conversion to the product (495%) can be obtained
using 50 equivalents of 2c after 1 h at 37 !C as confirmed by
liquid-chromatography–mass-spectrometry (LC–MS) analysis.
In this regard, the total protein content in the ion
chromatogram before and after the conjugation reaction is
analysed by MS and the protein concentration is analysed after
purification of the conjugate by Bradford protein assay, indicating
complete conversion to a single product in 495% yield (Fig. 2b
and Supplementary Fig. 13). Under identical conditions, pH 8.0
and 50 equivalents, the reaction of Annexin V with a maleimide
affords o50% of the expected conjugate with additional
modifications on Lys (data not shown).
Protein scope for Cys-bioconjugation. The scope of method
was then studied on different proteins (Fig. 3a) including an
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Figure 1 | Identification of a suitable carbonylacrylic derivative for reaction with Cys. (a) Reaction of 2a with N-Boc-Cys-OMe 1 provides the thioether
product 3a in 99% yield after 2min. (b) Reaction of 2a in an equimolar mixture of 1 and N-Boc-Lys-OMe 4 shows complete Cys chemoselectivity.
(c) Relative reaction rates at 25 !C (krel) calculated for the conjugate addition of methyl thiolate to maleimide and 3-carbonylacrylic acid derivatives 2a–d.
(d) Reaction of derivatives 2b–d with 1. (e) Experimental determination of the second-order rate constant for the addition of compound 2c to 1. See the
Supplementary Methods for additional details and kinetics data for compound 2a. (f) Kinetic assay for the stability of chromogenic thiol adducts 5 and 6 at
physiological pH. The absorbance of 5 at 410 nm is constant over time, indicating no release of 4-nitrophenolate. In contrast, for 6, a steady increase in
absorbance over time was observed. It is important to note that although both compounds absorb at 410 nm, we have set the initial absorbance to zero
for clarity. The original data for 5 (A0h¼0.45 nm, A5h¼0.45 nm) and for 6 (A0h¼0.23 nm, A5h¼0.35 nm) is presented in the Supplementary Fig. 7.
NR, no reaction; RT, room temperature.
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Figure 2 | Protein Cys bioconjugation with carbonylacrylic reagent 2c. (a) Schematic of the reaction of Cys-tagged proteins with carbonylacrylic reagents
2a–d. (b–d) Electrospray ionization–MS spectra of conjugates (b) Annexin V-2c, (c) C2Am-2c and (d) Albumin-2c. (e) MS/MS spectrum of the m/z
526.75 doubly charged ion of the tryptic peptide VPYCELGGK, containing the modification at the Cys residue of C2Am-2c. The generated C-terminal y
fragment ions (y6–y8) are consistent with the mass of the modification. (f) The albumin-2c conjugate remains intact when exposed to exogenous (GSH)
thiols and in plasma as assessed by LC–MS. See Supplementary Fig. 21. RT, room temperature; DMF, dimethylformamide.
Table 1 | Cys-bioconjugation on proteins.
Cys-protein (10mM) 2 Equivalent Temperature (!C) Time (h) Conversion (%)
Annexin V 2a 25 25 27 30w
Annexin V 2b 25 25 27 30w
Annexin V 2c 25 25 27 60
Annexin V 2d 25 25 27 0
Annexin V 2c 50 37 1 495
C2Am 2c 25 25 1 495
Albumin 2c 1 25 2 495
Identification of an efficient carbonylacrylic reagent and reaction optimization for site-selective Cys modification on proteins.*
*General bioconjugation conditions: protein (10 mM) in TrisHCl (pH 8.0, 20mM), carbonylacrylic derivative 2a–d (1–50 equiv.) dissolved in dimethylformamide (1–10%) were reacted in an Eppendorf
tube for the indicated time.
wHydrolysis of the ester was observed by LC–MS. See Supplementary Methods and Supplementary Figs 8–12 for full details. The bold numbers are the compound numbers.
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engineered variant of the C2A domain of Synaptotagmin-I
(C2Am), which is another apoptosis imaging agent23, as well as a
recombinant human albumin—Recombumin (Albumedix Ltd),
which has been used for example in drug-delivery applications
(Supplementary Figs 14–17; ref. 24). Both proteins have surface
exposed Cys residues and full conversion to the corresponding
thioether adducts could be obtained when reacted with 2c
(Fig. 2c,d). Much to our delight, we found that for albumin a
single equivalent of 2c is sufficient to achieve complete
conversion to the product, which demonstrates the high
efficiency of our method (Supplementary Figs 16 and 17).
While for certain less reactive Cys residues a slight excess of
reagent may be necessary (25–50 equivalents), stoichiometric Cys
selective modification may be attained depending on the local
geometry and chemical environment of Cys. The selectivity of the
carbonylacrylic reagents for Cys was corroborated using trypsin
digestion followed by peptide mapping using mass spectrometry
(Fig. 2e) or by chemical controls that involved Cys blocking
using Ellman’s reagent before reaction with 2c (Supplementary
Figs 18–20). Our data demonstrate that the new carbonylacrylic
reagents are highly selective for Cys at pH 8.0, which
contrasts with maleimides that show Lys cross-reactivity at
slightly basic pH (maleimide bioconjugation is usually performed
at slightly acidic pHB6.0 to 7.0 to avoid potential Lys
cross-reactivity).
Stability and binding of albumin conjugates. We next evaluated
the stability of the albumin conjugate with 2c in human plasma,
as well as in the presence of 10mM GSH (Fig. 2f). Importantly,
we observed that the thioether conjugate exhibited complete
resilience to degradation remaining intact, as demonstrated by
LC–MS analysis (Supplementary Fig. 21). Finally, by using
surface plasma resonance, we confirmed that the conjugate of
albumin retained its ability to bind to the neonatal Fc receptor
(FcRn)25 (KD (albumin)¼ 16.13mM; KD (albumin-2c)¼ 14.11mM)
(Supplementary Fig. 22). The data show the potential of our new
method to generate stable and functional protein conjugates for
in vivo applications.
Synthesis of functionalized carbonylacrylic reagents. To achieve
a general and effective bioconjugation method, it is important
that different functional groups can be readily attached to the
carbonylacrylic scaffold. Many relevant conjugation reagents such
as fluorescent probes, polyethylene glycol (PEG) derivatives or
drugs are commercially available bearing a free amine handle,
thus allowing for easy access to functionalized carbonylacrylic
reagents through amidation of the corresponding carboxylic acid
intermediate (see Supplementary Methods for synthetic details).
To further exemplify the utility of our method for bioconjugation
we synthesized a fluorescent carbonylacrylic derivative 7 bearing
nitrobenzofurazan (lexE465 nm and lemE539 nm) and a
a
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Figure 3 | Fluorescent labelling and PEGylation of proteins. (a) Scheme of the modification of albumin and Annexin V with fluorescent 7 or PEG 8
functionalized carbonylacrylic reagents. See Supplementary Methods for full synthetic details. (b) Treatment of Annexin V with 7 afforded a fluorescent
protein conjugate, as detected by SDS–polyacrylamide gel electrophoresis gel. Lanes 1 and 2, coommassie staining. Lanes 3 and 4, fluorescence.
(c) Fluorescence images of non-apoptotic (control) and apoptotic HEK293 cells after labelling with Annexin V-7. Blocking studies were performed by
pre-incubation of apoptotic cells with a 25$ excess of non-fluorescent Annexin V before incubation with Annexin V-7. (d) The mean fluorescent intensity
(MFI) showed a significant decrease of the binding of Annexin V-7 after blocking of the apoptotic receptors. Apoptotic cells appear green with the FITC
filter, while the nuclei are stained blue with the Hoechst dye. Scale bar, 100mm. s.d., standard deviation; a.u., arbitrary units; RT, room temperature.
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PEGylated derivative 8 (Fig. 3a) and showed that albumin could
be easily labelled using stoichiometric amounts of 7 or 8 within
1 to 2 h (Supplementary Figs 23–25).
Precise protein fluorescent labelling. Many maleimide-based
fluorescent labelling strategies, including those used to promote
hydrolysis, can lead to fluorescence quenching of the synthetic
probe attached to the protein19,26. To demonstrate the utility of
our method to fluorescently labelled proteins, we decided to
conjugate 7 to Annexin V and use the respective chemically
defined Annexin V fluorescent conjugate to specifically label
apoptotic cells by binding to the phosphatidylserine receptor on
their cell membrane. Remarkably, the Cys selective installation of
7 into Annexin V (Fig. 3b and Supplementary Figs 26 and 27; for
C2Am see Supplementary Figs 28 and 29) allowed for efficient
labelling and visualization of apoptotic HEK293 cells (Fig. 3c).
Moreover, the specificity of the observed labelling, which is
generated by the increase of the phosphatidylserine receptor in
the cell surface during apoptosis, was further confirmed through
blocking of cells with non-labelled Annexin V before incubation
with the fluorescently labelled Annexin V, which led to a
significant loss of fluorescence (Fig. 3c,d). Together, these data
not only demonstrated that probe fluorescence is retained after
functionalization of the protein with the carbonylacrylic reagent,
but also the utility of the method to create precisely modified
fluorescently labelled proteins that maintain high levels of specific
activity.
Cys-selective antibody conjugation. With a method in hand
suitable for rapid and irreversible bioconjugation of Cys-tagged
proteins, we next evaluated its application on antibody
conjugation. Much to our delight, we found that the conjugation
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Figure 4 | Construction of homogenous and functional antibody-conjugates. (a) Scheme for chemoselective and equimolar bioconjugation of
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reaction proceeded with stoichiometric amounts of 2c or 7 for
1 h at room temperature after tris(2-carboxyethyl)phosphine
reduction (Supplementary Figs 30 and 31) and dehydroascorbic
acid mediated disulfide re-oxidation of Trastuzumab LC-V205C
(Fig. 4a). Mass spectrometry analysis showed a single modifica-
tion in the light chain (Fig. 4b,c and Supplementary Fig. 32) while
the heavy chain remained unmodified (Supplementary Fig. 33).
This indicates a successful re-oxidation of the interchain
disulfides with conjugation occurring only at the engineered free
Cys in the light-chain, yielding a pure and chemically defined
conjugate. Notably, our method improves the homogeneity, the
quality of the antibody conjugate product, as conjugates of
Trastuzumab LC–V205C prepared using maleimides result in a
mixture of modified (B80–90%) and non-modified species
(B10–20%; refs 13,16,27,28). Importantly, the Trastuzumab-2c
conjugate retained its binding activity to the HER2 antigen
(KD¼ 11±2.3 nM for the conjugate versus KD¼ 14±1.4 nM for
the unmodified antibody) as shown by bio-layer interferometry
(BLI) (Fig. 4d and Supplementary Fig. 34). These results were
corroborated by enzyme-linked immunosorbent assay
(Supplementary Fig. 35). We also show by flow-cytometry
analysis and using fluorescently labelled Trastuzumab-7
(Supplementary Fig. 36) that the modified antibody retains its
specificity towards SKBR3 cells, which express high levels of its
target antigen (her2/c-erb-2), as opposed to HepG2 cells, which
express low levels of its target (Fig. 4e,f and Supplementary
Discussion). Moreover, fluorescently labelled Trastuzumab-7
appears to be specific to her2/c-erb-2 receptors at an identical
antibody concentration to that previously reported for
Trastuzumab29. Also, at 150 nM, percentages of her2–positive
cells in each cell line also are in accordance with previous reports
using Trastuzumab and other commercially available antibodies
targeting her2–receptors29. At higher concentrations, we observed
unspecific binding of the antibody, while at concentrations lower
than 10 nM, there was no observable staining (data not shown).
Our flow-cytometry data clearly shows that the modified
Trastzumab-7 retains its specificity towards her2 receptors.
Together, these results demonstrate the utility of our new
bioconjugation method for the generation of homogenous and
functional antibody-conjugates using equimolar (1 equivalent per
Cys) quantities of the carbonylacrylic reagents here reported.
In summary, a one-step and irreversible Cys selective
bioconjugation is reported using simple carbonylacrylic reagents.
The reaction proceeds with a high degree of Cys selectivity using
equimolar amounts of synthetically accessible reagents under
aqueous biologically friendly conditions. The conjugates formed
are fully stable when exposed to GSH and in plasma, and retain
their function, as evidenced by the selective imaging and
detection of apoptotic and HER2–positive cells, respectively.
The superior reactivity and Cys selectivity of the carbonylacrylic
reagents enable access to fully homogenous conjugates including
the antibody Trastuzumab as opposed to the antibody conjugate
prepared using maleimides. Our method is likely to be of a
general benefit for other sensitive Cys-tagged protein/antibody
systems, many of which are already available through large-scale
production. As such, we are confident that the direct chemose-
lective and irreversible Cys bioconjugation technology disclosed
herein will find a significant use for the preparation of imaging
and therapeutic conjugates for in vivo purposes.
Methods
Synthetic details. For detailed procedures and characterization, see the
Supplementary Methods. For 1H and 13C NMR spectra of the compounds in this
article, see Supplementary Figs 37–46.
General procedure for antibody conjugation. Trastuzumab LC-V205C (15 ml,
400 nmol) disulfide bonds were reduced by mild reduction in TrisHCl (pH 8.0,
20mM) (23 ml) at 25 !C by the addition of tenfold molar excess reducing agent
tris(2-carboxyethyl)phosphine (1 ml, 4,000 mM) for 1.5 h, followed by filtration
using a Zeba Spin Desalting Column previously equilibrated with TrisHCl (pH 8.0,
20mM). The sample was eluted via centrifugation (2min, 1,500g). To re-form the
interchain disulfide bonds, the reduced Trastuzumab was incubated for 4 h at 25 !C
with dehydroascorbic acid at a tenfold molar excess. After, a 5 ml aliquot of reaction
mixture was analysed by LC–MS (a 5 ml aliquot was diluted with 5 ml TrisHCl
buffer (pH 8.0, 20mM)). Finally, to an eppendorf with 20 ml of re-oxidized
Trastuzumab LC-V205C was added a 0.48 ml aliquot of a stock solution of 2c
or 7 (1 equivalent/Cys) in dimethylformamide (1% of total volume) and the
reaction was mixed for 1 h at room temperature. A 10 ml aliquot was analysed by
LC–MS and complete conversion to the expected product was observed, that is,
modification of the Cys on the light chain (Supplementary Fig. 32) and no mod-
ification in the heavy-chain (Supplementary Fig. 33).
LC–MS analysis of protein conjugation. LC–MS was performed on a Xevo G2-S
TOF mass spectrometer coupled to an Acquity high-performance liquid chroma-
tography (UPLC) system using an Acquity UPLC BEH300 C4 column (1.7 mm,
2.1$ 50mm). Solvents A, a water with 0.1% formic acid and B, 71% acetonitrile,
29% water and 0.075% formic acid were used as the mobile phase at a flow rate of
0.2mlmin–1. The gradient was programmed as follows: 72% A to 100% B after
25min then 100% B for 2min and after that 72% A for 18min. The electrospray
source was operated with a capillary voltage of 2.0 kV and a cone voltage of 40V.
Nitrogen was used as the desolvation gas at a total flow of 850 l h–1. Total mass
spectra were reconstructed from the ion series using the MaxEnt algorithm pre-
installed on MassLynx software (v. 4.1 from Waters) according to the manu-
facturer’s instructions. To obtain the ion series described, the major peak(s) of the
chromatogram were selected for integration and further analysis. See
Supplementary Fig. 13.
Tryptic digestion and MS/MS analysis. The protein solution was reduced,
alkylated and digested with trypsin overnight. Post-digestion, the solution was
pipetted into a vial and placed in the autosampler of the LC pump. All LC–MS/MS
experiments were performed using a Dionex Ultimate 3,000 RSLC nanoUPLC
(Thermo Fisher Scientific Inc, Waltham, MA, USA) system and a QExactive
Orbitrap mass spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA).
Separation of peptides was performed by reverse-phase chromatography at a flow
rate of 300 nlmin" 1 and a Thermo Scientific reverse-phase nano Easy-spray
column (Thermo Scientific PepMap C18, 2 mm particle size, 100A pore size,
75 mm$ 50 cm length). Peptides were loaded onto a pre-column (Thermo Scien-
tific PepMap 100 C18, 5 mm particle size, 100A pore size, 300 nm$ 5mm length)
from the Ultimate 3,000 autosampler with 0.1% formic acid for 3min at a flow rate
of 10ml min" 1. After this period, the column valve was switched to allow elution of
peptides from the pre-column onto the analytical column. Solvent A was water
þ 0.1% formic acid and solvent B was 80% acetonitrile, 20% water þ 0.1% formic
acid. The linear gradient employed was 2–40% B in 30min. The LC eluent was
sprayed into the mass spectrometer by means of an Easy-spray source (Thermo
Fisher Scientific Inc.). All m/z values of eluting ions were measured in an Orbitrap
mass analyser, set at a resolution of 70,000. Data dependent scans (Top 20) were
employed to automatically isolate and generate fragment ions by higher energy
collisional dissociation in the quadrupole mass analyser and measurement of the
resulting fragment ions was performed in the Orbitrap analyser, set at a resolution
of 17,500. Peptide ions with charge states of 2þ and above were selected for
fragmentation. Post-run, the data was processed using Protein Discoverer (version
1.4., ThermoFisher). Briefly, all MS/MS data were converted to mgf files and these
were submitted to the Mascot search algorithm (Matrix Science, London UK) and
searched against a custom database containing the C2A domain of synaptotagmin-
I sequence and applying a fixed modification of carbamidomethyl (C) and variable
modifications of oxidation (M), deamidation (NQ) and a custom modification of
C2Am-2c (C), using a peptide tolerance of 5 p.p.m. (MS) and 0.1Da (MS/MS).
Peptide identifications were accepted if they could be established at 495.0%
probability.
Protein gels. The incubation solution (5.0 ml) was transferred to tube, and
NuPAGE LDS Sample Buffer (4$ , 2.5 ml), NuPAGE Reducing Agent (10$ , 1 ml),
and H2O (1.5 ml) were added to the tube. The solution was heated at 70 !C for
10min. The heated solution was loaded to NuPAGE Bis-Tris mini gel (10$ 10 cm)
with 4–12% gradient polyacrylamide concentration, and then the conjugation
reaction was analysed by electrophoresis (200V). The buffering system employed
was 1$ SDS Running Buffer (NuPAGE MES SDS Running Buffer, 20$ , pH 7.3,
50 to 950ml deionized water). For reduced samples, 500 ml of NuPAGE
Antioxidant was added to each 200ml 1$ SDS running buffer. After 35min, the
intensities of fluorescence were analysed. Then, the gel was stained with 0.5% of
Ruby. The gel was mixed overnight at room temperature and read the day after.
After washing the gel, coomassie (0.5%) was added and the gel was read 2 h after
mixing at room temperature. See Supplementary Figs 24, 27, 29 and 36.
Microscopy studies. Human embryonic kidney HEK293 cells were maintained at
37 !C in a humidified atmosphere of 5% CO2 in DMEM high glucose (Gibco)
supplemented with 10% heat inactivated fetal bovine serum (HI-FBS, Gibco) and
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1X antibiotic-antimycotic (Gibco). When cells have reached the appropriate
density (70–80% confluent), the medium was aspirated and cells harvested with
0.25% Trypsin-EDTA. Then, 200ml of the cell suspension (B50,000 cells) was
applied on top of 12mm glass coverslips pre-coated with poly D-lysine (Corning
BioCoat) placed inside a 24-well plate. After 1 h of incubation to allow cells to
adhere, 200 ml of additional media was added to flood the wells. Cells were then
grown for more 7 h at 37 !C before apoptosis was induced by treatment for 12 h
with 2 mM of actinomycin D in fresh growth media. Untreated cells at the same
density were included as a control. After apoptosis induction the media was
removed, cells were washed with D-PBS (Gibco) and incubated at 37 !C for 20min
with 7 at a concentration of 0.2 mM in 10mM HEPES pH 7.4 supplemented with
140mM NaCl and 2.5mM CaCl2 (annexin binding buffer from Molecular Probes).
At the same time blocking studies were performed by pre-incubating apoptotic
cells with a 25$ excess of non-fluorescent Annexin V wild type (5 mM, 37 !C for
20min) before incubation with the fluorescent probe 7 for additional 20min at
37 !C. For fluorescent DNA nuclei staining, Hoechst 33,342 (0.8 mgml" 1, Sigma
Aldrich, 15min at 37 !C) was used. After labelling, the cells were washed with PBS
two times. Finally, cells were fixed with PBS containing 4% (w/v) formaldehyde for
15min at room temperature, further washed two times with PBS, and mounted on
slides with Ibidi mounting medium. Fluorescence microscopy was performed using
an inverted epifluorescent microscope (Olympus IX-71) connected to a F-view
digital camera (Soft Imaging System). Images were acquired in the fluorescein
isothiocyanate (FITC) and Hoechst channels and analysed using the software
Cell-F. Identical image acquisition settings were used for the control, experimental
and blocking data sets.
Determination of antibody conjugates binding affinity. Biotinylation of
antibodies. Non-modified Trastuzumab and Trastuzumab-2c were conjugated to a
biotin linker using Biotin-(PEG)4-N-hydroxysuccinimide(NHS) (Thermofisher
Scientific) in order to carry out BLI experiments using Streptavidin (SA) Bio-
sensors. A solution of EZ-Link NHS-(PEG)4-Biotin (20 ml, 200mM in PBS) was
added to the corresponding protein (20 ml, 20 mM in PBS) and was left at room
temperature for 30min. The crude reaction mixture was buffer exchanged with
PBS for three times to remove the excess of NHS-(PEG)4-Biotin, obtaining a
biotin-to-antibody ratio around 1.6.
Bio-layer interferometry. Binding assays were performed on an Octet Red
Instrument (forte´BIO). Ligand immobilization, binding reactions, regeneration and
washes were conducted in wells of black polypropylene 96-well microplates.
Trastuzumab and Trastuzumab-2c (20 nM) were immobilized on Streptavidin (SA)
Biosensors in PBS with 0.1% BSA and 0.02% tween at 30 !C. Binding analysis were
carried out at 25 !C, 1,000 r.p.m. in PBS pH 7.4 with 0.1% BSA and 0.02% tween,
with a 600 s of association followed by a 2,200 s of dissociation, using different
concentrations of the recombinant HER2 receptor to obtain the association curve.
Glycine pH 2.0 was used as a regeneration buffer. Data were analysed using Data
Analysis (forte´BIO), with Savitzky-Golay filtering. Binding was fitted to a 2:1
Heterogeneous ligand model, steady state analysis were performed to obtain the
binding kinetics constants (KD). See Supplementary Fig. 34.
Determination of antibody conjugates specificity. Cell culture conditions.
SKBR3 (ATCC HTB-30) and HepG2 (ATCC HB-8065) cells were routinely grown
in a humidified incubator at 37 !C under 5% CO2 and split before reaching con-
fluence using TrypLE Express. Both cells lines were grown in DMEM medium
supplemented with 10% heat-inactivated FBS, 2mM GlutaMAX, 10mM HEPES,
1% non-essential amino acids (NEAA), 1mM sodium pyruvate, 100 unitsml" 1
penicillin and 100 mgml" 1 streptomycin. All reagents were bought from Gibco,
Life Technologies (USA), unless otherwise stated.
Flow cytometry. SKBR3 and HepG2 cells were seeded in 24 well-plates at a
concentration of 50,000 cells per well and 30,000 cells per well, respectively, and
cultured for 48 h before being used for experimentation. Cells were detached from
the plates and collected into flow cytometry round bottom polystyrene tubes.
Culture medium was removed and cells were re-suspended in complete medium
supplemented with either Trastuzumab or Trastuzumab-7 (at 5, 10, 50, 150, 300
and 500 nM) and incubated at room temperature, in the dark. After 1 h, cell
suspensions were centrifuged at 400 g for 4min, the medium was removed and cells
were re-suspended in 300ml of a PBS solution supplemented with 10% FBS. Cells
were kept in the dark until analysis. Acquisition was performed on a
LSRFortessaTM flow cytometer (BD Biosciences, USA) set up with a 488 nm laser
and a combination of a 505 nm long-pass and a 530/30 nm band-pass filter
(combination used for FITC detection). Due to expected overlap between the
emission spectrum of Trastuzumab-7 with the one of R-phycoerythrin (PE)
channels, data were also acquired with the combination of filters normally used for
its detection (a 550 nm long-pass and a 575/26 nm band-pass filter), and
compensation was performed between these channels. Only results for single-cell
events are shown, and data are expressed as the average of three independent
experiments±s.e.m.
Data availability. Additional information and the data supporting this research
are available within the article and the Supplementary Information file and from
the corresponding author upon reasonable request.
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